Advanced

Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival

Olsson-Stromberg, U; Simonsson, B; Ahlgren, T; Bjorkholm, M; Carlsson, K; Gahrton, G; Hast, R; Lofvenberg, E; Linder, O and Ljungman, P, et al. (2004) In The Hematology Journal 5(6). p.462-466
Abstract
Introduction: Whether busulphan -treated patients develop blastic transformation earlier than hydroxyurea treated has been a controversial issue. In a randomised prospective study, we examined the busulphan versus hydroxyurea influence on time to blast crisis and on survival. When we opened our study in 1984, the clinical benefit of allogeneic bone marrow transplantation (BMT) was not well known; to follow up the long-time outcome of this treatment was therefore of great interest. Materials and methods: Previously untreated CML patients were randomly started on either hydroxyurea (30 mg/kg/day) or busulphan (0. 1 mg/kg/day). The end points of the study were overall survival and time to blast crisis. A total of 26 patients subsequently... (More)
Introduction: Whether busulphan -treated patients develop blastic transformation earlier than hydroxyurea treated has been a controversial issue. In a randomised prospective study, we examined the busulphan versus hydroxyurea influence on time to blast crisis and on survival. When we opened our study in 1984, the clinical benefit of allogeneic bone marrow transplantation (BMT) was not well known; to follow up the long-time outcome of this treatment was therefore of great interest. Materials and methods: Previously untreated CML patients were randomly started on either hydroxyurea (30 mg/kg/day) or busulphan (0. 1 mg/kg/day). The end points of the study were overall survival and time to blast crisis. A total of 26 patients subsequently underwent BMT. Results: A total of 179 patients were randomised.. 90 to hydroxyurea, and 89 to busulphan treatment. There was no significant difference in survival between hydroxyurea- and busulphantreated patients (P=0.46) median survival was 3.5 and 3.2 years, respectively. In all, 85 of the patients were subsequently diagnosed with blast crisis, 41 in the busulphan and 44 in the hydroxyurea group. There was no significant difference between the two groups (P = 0.91). The 26 patients who were allotransplanted survived significantly longer than those who were not transplanted (P=0.0001). The 5-year-survival rates were 50 and 22% and the 10-year-survival rates were 46 and 2%, respectively. The median survival was 4.7 years for the transplanted and 3.3 years for the nontransplanted patients. Conclusion: We did not find any difference between hydroxyurea and busulphan treatment, either in overall survival or in blast crisis-free survival; transplanted patients survived significantly longer than nontransplanted patients. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
hydroxyurea, marrow transplantation, busulphan, bone, randomised, chronic myeloid leukaemia
in
The Hematology Journal
volume
5
issue
6
pages
462 - 466
publisher
Nature Publishing Group
external identifiers
  • pmid:15570285
  • wos:000227379500001
  • scopus:19944406090
ISSN
1476-5632
language
English
LU publication?
yes
id
005b6736-7428-4c73-b983-df21201059e5 (old id 897233)
date added to LUP
2008-01-18 10:46:11
date last changed
2017-01-01 04:30:27
@article{005b6736-7428-4c73-b983-df21201059e5,
  abstract     = {Introduction: Whether busulphan -treated patients develop blastic transformation earlier than hydroxyurea treated has been a controversial issue. In a randomised prospective study, we examined the busulphan versus hydroxyurea influence on time to blast crisis and on survival. When we opened our study in 1984, the clinical benefit of allogeneic bone marrow transplantation (BMT) was not well known; to follow up the long-time outcome of this treatment was therefore of great interest. Materials and methods: Previously untreated CML patients were randomly started on either hydroxyurea (30 mg/kg/day) or busulphan (0. 1 mg/kg/day). The end points of the study were overall survival and time to blast crisis. A total of 26 patients subsequently underwent BMT. Results: A total of 179 patients were randomised.. 90 to hydroxyurea, and 89 to busulphan treatment. There was no significant difference in survival between hydroxyurea- and busulphantreated patients (P=0.46) median survival was 3.5 and 3.2 years, respectively. In all, 85 of the patients were subsequently diagnosed with blast crisis, 41 in the busulphan and 44 in the hydroxyurea group. There was no significant difference between the two groups (P = 0.91). The 26 patients who were allotransplanted survived significantly longer than those who were not transplanted (P=0.0001). The 5-year-survival rates were 50 and 22% and the 10-year-survival rates were 46 and 2%, respectively. The median survival was 4.7 years for the transplanted and 3.3 years for the nontransplanted patients. Conclusion: We did not find any difference between hydroxyurea and busulphan treatment, either in overall survival or in blast crisis-free survival; transplanted patients survived significantly longer than nontransplanted patients.},
  author       = {Olsson-Stromberg, U and Simonsson, B and Ahlgren, T and Bjorkholm, M and Carlsson, K and Gahrton, G and Hast, R and Lofvenberg, E and Linder, O and Ljungman, P and Malm, C and Paul, C and Rodjer, S and Turesson, Ingemar and Uden, AM and Wahlin, A and Killander, A and Wadman, B and Westin, J and Vikrot, O and Zettervall, O and Oberg, G},
  issn         = {1476-5632},
  keyword      = {hydroxyurea,marrow transplantation,busulphan,bone,randomised,chronic myeloid leukaemia},
  language     = {eng},
  number       = {6},
  pages        = {462--466},
  publisher    = {Nature Publishing Group},
  series       = {The Hematology Journal},
  title        = {Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival},
  volume       = {5},
  year         = {2004},
}